Comparative activity of antiemetic drugs
Authors:
- Karin JordanKJKarin Jordan
- Hans J. SchmollHSHans J. Schmoll
- Matti S. AaproMAMatti S. Aapro
- 1 February 2007
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 61 (2) , 162-175
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006Journal of Clinical Oncology, 2006
- Anticipatory nausea and vomitingSupportive Care in Cancer, 2004
- Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an updateSupportive Care in Cancer, 2004
- Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapySupportive Care in Cancer, 2004
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomitingCancer, 2003
- Delayed emesis: incidence, pattern, prognostic factors and optimal treatmentSupportive Care in Cancer, 2002
- Nausea and emesis: still an unsolved problem in cancer patients?Supportive Care in Cancer, 2002
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- Comparative aspects of the area postrema: fine-structural considerations help to determine its functionCellular and Molecular Neurobiology, 1986